Analysis Group, Inc., Boston, MA 02199, USA.
US Medical Affairs, AstraZeneca, Gaithersburg, MD 20878, USA.
Future Oncol. 2019 Oct;15(29):3381-3393. doi: 10.2217/fon-2019-0282. Epub 2019 Sep 23.
To analyze treatment patterns and overall survival (OS) across time (2009-2014) among patients with unresected, stage III non-small-cell lung cancer (NSCLC). Stage III NSCLC patients aged ≥65 years who initiated therapy were identified using SEER-Medicare data. Among 4564 patients, 84% received chemotherapy (with or without radiotherapy), and 59% received chemoradiotherapy (CRT). Carboplatin + paclitaxel was the most frequent regimen. Median (interquartile range) OS among chemotherapy patients was 13.2 (6.0-28.9) months, and 14.8 (6.7-33.4) months among CRT patients. Among CRT patients, there was no difference in OS across years of CRT initiation. OS remained static across 2009-2014, indicating stagnancy in clinical outcomes for stage III NSCLC patients and a need for more effective therapeutic options.
分析未经手术切除的 III 期非小细胞肺癌（NSCLC）患者随时间（2009-2014 年）的治疗模式和总生存期（OS）。使用 SEER-Medicare 数据确定年龄≥65 岁开始治疗的 III 期 NSCLC 患者。在 4564 名患者中，84%接受化疗（联合或不联合放疗），59%接受放化疗（CRT）。卡铂+紫杉醇是最常见的方案。化疗患者的中位（四分位间距）OS 为 13.2（6.0-28.9）个月，CRT 患者为 14.8（6.7-33.4）个月。在 CRT 患者中，CRT 起始年份之间的 OS 无差异。2009-2014 年 OS 保持稳定，表明 III 期 NSCLC 患者的临床结局停滞不前，需要更有效的治疗选择。
